Co-Diagnostics Inc

Revolutionary Molecular Diagnostics - we are a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests

[Co-Diagnostics Inc @Co_Diagnostics]

Empowering patients and providers through accessible, reliable diagnostics is the mission behind CoMira Diagnostics, our new joint venture in the Kingdom of Saudi Arabia

https://t.co/e0fYqEypz5

$CODX #CoDiagnostics #GlobalHealth #PCR #Diagnostics #KSA

[Co-Diagnostics Inc @Co_Diagnostics]

$CODX has signed an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR Pro® instrument and tests, advancing its Latin American commercialization strategy ahead of the platform’s market launch.

Details: https://t.co/CocOWIyzkU

[Co-Diagnostics Inc @Co_Diagnostics]

Co-Diagnostics and CoSara Diagnostics are advancing dual-assay Ebola PCR testing to detect and differentiate ebolavirus strains in Central Africa, and to introduce blood-based pathogen testing on the Co-Dx PCR point-of-care platform.

Read more: https://t.co/buoSCBRUEY

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

CoDx has advanced its PCR assay development strategy for BDBV tied to the current Ebola outbreak, with support from CoSara Diagnostics.

The program supports rapid response to emerging infectious disease threats and global health initiatives.

https://t.co/gyLxuZzplB

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Emerging infectious disease threats continue to highlight the importance of decentralized diagnostics and rapid PCR testing. Co-Diagnostics has completed the assay development strategy for BDBV associated with the current Ebola outbreak.

Read more: https://t.co/5zFDF0cktw

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

With a simplified workflow, fewer manual steps than other platforms, an extraction-free process, and easy-to-read results, the Co-Dx PCR platform delivers. Featuring the Co-Dx PCR Pro® instrument and Co-Dx PCR test cups, all designed for easy results with minimal hands-on time.

[Co-Diagnostics Inc @Co_Diagnostics]

CoMira Diagnostics has finalized a lease for a manufacturing facility in Sudair Industrial City, supporting localized manufacturing of molecular diagnostics in alignment with #Vision2030.

Read more:
https://t.co/0L0YLXbY5o

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Tune in on Thursday, May 14, 2026, at 4:30 p.m. ET for Co-Diagnostics’ Q1 2026 earnings call, where we’ll discuss financial results and business outlook.

Details: https://t.co/J76kjBxKkW

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Join Co-Dx at ESCMID Global as we showcase our latest PCR technology.

Stop by to connect with our team, explore what's coming next, and see how Co-Dx is helping shape the future of PCR diagnostics.

[Co-Diagnostics Inc @Co_Diagnostics]

Co-Diagnostics will present its Co-Dx™ MTB test at the @StopTB Summit.

The event brings together government agencies and private sector organizations focused on TB solutions.

Details: https://t.co/656TjZksnX

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Co-Diagnostics is participating in the WTC Utah Trade Mission:

April 13–22, 2026 | Switzerland & Germany

We will engage with global leaders in diagnostics, R&D, and finance.

Details: https://t.co/ZOSbgkLnDv

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Global expansion continues to progress at @Co_Diagnostics.

CEO Dwight Egan discusses the Company’s latest joint venture agreement in the Kingdom of Saudi Arabia.

https://t.co/R3efesDHka

$CODX #GlobalHealth #Biotech

[Co-Diagnostics Inc @Co_Diagnostics]

CoMira has received approval for a new manufacturing facility in Sudair Industrial City, which is expected to position the JV as an early domestic manufacturer of molecular diagnostic solutions in Saudi Arabia and support #Vision2030.

Details: https://t.co/aVH5RvpeGJ $CODX

[Co-Diagnostics Inc @Co_Diagnostics]

@Co_Diagnostics has begun shipping PCR Pro® instruments and TB test kits to India to support clinical studies. This effort aligns with new @/WHO guidance on expanding access to TB testing.

Details: https://t.co/fdG4I9HmgV

$CODX #ENDTB #PCR

[Co-Diagnostics Inc @Co_Diagnostics]

Tuberculosis remains the world’s deadliest infectious disease, yet access to timely, accurate diagnosis is still out of reach for many. This #WorldTBDay2026, we’re focused on closing that gap.

[Co-Diagnostics Inc @Co_Diagnostics]

Join Co-Dx at the AMCA Annual meeting from March23-26 at Booth 326. Stop by our booth and let us show you how easily PCR technology can be used in your district, and why so many are making the switch to in-house testing with Co-Dx Vector Smart® mosquito PCR tests.

[Co-Diagnostics Inc @Co_Diagnostics]

Expanding into Bangladesh, Pakistan, Nepal, and Sri Lanka marks a critical step for @Co_Diagnostics growth strategy in high-demand molecular diagnostics markets.

Details: https://t.co/2ZYP1XAC1m

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

@Co_Diagnostics CEO Dwight Egan discusses the important role of India in the Company’s past and future with @Nasdaq's @kristinaayanian.

https://t.co/s7qRZccUUj

$CODX #GlobalHealth #Biotech

[Co-Diagnostics Inc @Co_Diagnostics]

@Co_Diagnostics is attending #MedicalKorea2026 in Seoul to present our Co-Dx PCR point-of-care platform and connect with global partners.

Details: https://t.co/oPzVoW5KFJ
$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

Co-Diagnostics has been granted a patent by the Japan Patent Office, further strengthening global protection of our Co-Dx PCR platform technologies.

Details: https://t.co/CUbTgPSbHw

$CODX

[Co-Diagnostics Inc @Co_Diagnostics]

@Co_Diagnostics has regained full compliance with Nasdaq listing requirements, and its shares will resume trading on the Nasdaq Capital Market on March 11, 2026. $CODX

Read more: https://t.co/wdpQ87qcAq